MACROGENICS, INC. Inventory, Work in Process, Gross
MACROGENICS, INC. (MGNX) had Inventory, Work in Process, Gross of $2.19 million as of 2024-09-30, per its 10-Q filed 2024-11-05.
Financial Statements › Balance Sheet › Assets › Assets, Current › Inventory, Net
us-gaap:InventoryWorkInProcess · last filed 2025-03-20
- 2024-09-30: Inventory, Work in Process, Gross $2.19M.
- 2024-06-30: Inventory, Work in Process, Gross $0.00.
- 2024-03-31: Inventory, Work in Process, Gross $209.00K.
- 2023-12-31: Inventory, Work in Process, Gross $261.00K.
| Period end | Inventory, Work in Process, Gross |
|---|---|
| 2024-09-30 | $2.19M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-06 |
| 2024-03-31 | $209.00K 10-Q · filed 2024-05-09 |
| 2023-12-31 | $261.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-06 |
| 2023-06-30 | $221.00K 10-Q · filed 2023-08-09 |
| 2023-03-31 | $206.00K 10-Q · filed 2023-05-09 |
| 2022-12-31 | $409.00K 10-K · filed 2024-03-07 |
| 2022-09-30 | $209.00K 10-Q · filed 2022-11-03 |
| 2022-06-30 | $2.23M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $3.72M 10-Q · filed 2022-05-03 |
| 2021-12-31 | $3.93M 10-K · filed 2023-03-15 |
| 2021-09-30 | $3.10M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $5.87M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $4.96M 10-Q · filed 2021-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |